Literature DB >> 24958854

C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis.

Cailin Collins1, Jingya Wang1, Hongzhi Miao1, Joel Bronstein1, Humaira Nawer1, Tao Xu1, Maria Figueroa1, Andrew G Muntean1, Jay L Hess2.   

Abstract

Homeobox A9 (HOXA9) is a homeodomain-containing transcription factor that plays a key role in hematopoietic stem cell expansion and is commonly deregulated in human acute leukemias. A variety of upstream genetic alterations in acute myeloid leukemia (AML) lead to overexpression of HOXA9, almost always in association with overexpression of its cofactor meis homeobox 1 (MEIS1) . A wide range of data suggests that HOXA9 and MEIS1 play a synergistic causative role in AML, although the molecular mechanisms leading to transformation by HOXA9 and MEIS1 remain elusive. In this study, we identify CCAAT/enhancer binding protein alpha (C/EBPα) as a critical collaborator required for Hoxa9/Meis1-mediated leukemogenesis. We show that C/EBPα is required for the proliferation of Hoxa9/Meis1-transformed cells in culture and that loss of C/EBPα greatly improves survival in both primary and secondary murine models of Hoxa9/Meis1-induced leukemia. Over 50% of Hoxa9 genome-wide binding sites are cobound by C/EBPα, which coregulates a number of downstream target genes involved in the regulation of cell proliferation and differentiation. Finally, we show that Hoxa9 represses the locus of the cyclin-dependent kinase inhibitors Cdkn2a/b in concert with C/EBPα to overcome a block in G1 cell cycle progression. Together, our results suggest a previously unidentified role for C/EBPα in maintaining the proliferation required for Hoxa9/Meis1-mediated leukemogenesis.

Entities:  

Keywords:  enhancer; gene regulation

Mesh:

Substances:

Year:  2014        PMID: 24958854      PMCID: PMC4103350          DOI: 10.1073/pnas.1402238111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  The Hox genes and their roles in oncogenesis.

Authors:  Nilay Shah; Saraswati Sukumar
Journal:  Nat Rev Cancer       Date:  2010-04-01       Impact factor: 60.716

2.  SnapShot: Acute myeloid leukemia.

Authors:  Bernd B Zeisig; Austin G Kulasekararaj; Ghulam J Mufti; Chi Wai Eric So
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

Review 3.  Hox genes in vertebrate development.

Authors:  R Krumlauf
Journal:  Cell       Date:  1994-07-29       Impact factor: 41.582

Review 4.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

5.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities.

Authors:  Sven Heinz; Christopher Benner; Nathanael Spann; Eric Bertolino; Yin C Lin; Peter Laslo; Jason X Cheng; Cornelis Murre; Harinder Singh; Christopher K Glass
Journal:  Mol Cell       Date:  2010-05-28       Impact factor: 17.970

Review 6.  Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.

Authors:  Brunangelo Falini; Paolo Sportoletti; Maria Paola Martelli
Journal:  Curr Opin Oncol       Date:  2009-11       Impact factor: 3.645

7.  NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.

Authors:  Gang G Wang; Ling Cai; Martina P Pasillas; Mark P Kamps
Journal:  Nat Cell Biol       Date:  2007-06-24       Impact factor: 28.824

Review 8.  The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.

Authors:  R T Williams; C J Sherr
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2008-11-21

9.  Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells.

Authors:  Lan-Lan Smith; Jenny Yeung; Bernd B Zeisig; Nikolay Popov; Ivo Huijbers; Josephine Barnes; Amanda J Wilson; Erdogan Taskesen; Ruud Delwel; Jesús Gil; Maarten Van Lohuizen; Chi Wai Eric So
Journal:  Cell Stem Cell       Date:  2011-06-03       Impact factor: 24.633

10.  Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.

Authors:  Hong Zhang; Meritxell Alberich-Jorda; Giovanni Amabile; Henry Yang; Philipp B Staber; Annalisa Di Ruscio; Annalisa Diruscio; Robert S Welner; Alexander Ebralidze; Junyan Zhang; Elena Levantini; Véronique Lefebvre; Peter J M Valk; Ruud Delwel; Maarten Hoogenkamp; Claus Nerlov; Jörg Cammenga; Borja Saez; David T Scadden; Constanze Bonifer; Min Ye; Daniel G Tenen
Journal:  Cancer Cell       Date:  2013-10-31       Impact factor: 31.743

View more
  39 in total

1.  C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia.

Authors:  Justin Loke; Paulynn Suyin Chin; Peter Keane; Anna Pickin; Salam A Assi; Anetta Ptasinska; Maria Rosaria Imperato; Peter N Cockerill; Constanze Bonifer
Journal:  Blood Adv       Date:  2018-02-13

2.  Hhex is Required at Multiple Stages of Adult Hematopoietic Stem and Progenitor Cell Differentiation.

Authors:  Charnise Goodings; Elizabeth Smith; Elizabeth Mathias; Natalina Elliott; Susan M Cleveland; Rati M Tripathi; Justin H Layer; Xi Chen; Yan Guo; Yu Shyr; Rizwan Hamid; Yang Du; Utpal P Davé
Journal:  Stem Cells       Date:  2015-05-27       Impact factor: 6.277

3.  Histone deacetylase inhibitors induce leukemia gene expression in cord blood hematopoietic stem cells expanded ex vivo.

Authors:  Yuk Man Lam; Yuen Fan Chan; Li Chong Chan; Ray Kit Ng
Journal:  Int J Hematol       Date:  2016-08-16       Impact factor: 2.490

Review 4.  Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets.

Authors:  C T Collins; J L Hess
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

5.  Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.

Authors:  Sujitha Duggimpudi; Andreas Kloetgen; Sathish Kumar Maney; Philipp C Münch; Kebria Hezaveh; Hamed Shaykhalishahi; Wolfgang Hoyer; Alice C McHardy; Philipp A Lang; Arndt Borkhardt; Jessica I Hoell
Journal:  J Biol Chem       Date:  2018-08-20       Impact factor: 5.157

Review 6.  C/EBPα deregulation as a paradigm for leukemogenesis.

Authors:  J A Pulikkan; D G Tenen; G Behre
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

7.  Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.

Authors:  Seiko Yoshino; Takashi Yokoyama; Yoshitaka Sunami; Tomoko Takahara; Aya Nakamura; Yukari Yamazaki; Shuichi Tsutsumi; Hiroyuki Aburatani; Takuro Nakamura
Journal:  Blood       Date:  2021-01-07       Impact factor: 22.113

8.  HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Authors:  Yuqing Sun; Bo Zhou; Fengbiao Mao; Jing Xu; Hongzhi Miao; Zhenhua Zou; Le Tran Phuc Khoa; Younghoon Jang; Sheng Cai; Matthew Witkin; Richard Koche; Kai Ge; Gregory R Dressler; Ross L Levine; Scott A Armstrong; Yali Dou; Jay L Hess
Journal:  Cancer Cell       Date:  2018-09-27       Impact factor: 31.743

Review 9.  C/EBPα in normal and malignant myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

10.  The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.

Authors:  C O'Connor; F Lohan; J Campos; E Ohlsson; M Salomè; C Forde; R Artschwager; R M Liskamp; M R Cahill; P A Kiely; B Porse; K Keeshan
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.